Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10253556 | 0.95 | MTNR1A (0.61) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL10247271 | 0.90 | HDAC8 (0.68) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL355780 | 0.88 | CA1 (0.58) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL355014 | 0.88 | CA1 (0.58) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL355015 | 0.88 | CA1 (0.58) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3395108 | 0.84 | CA1 (0.64) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL10246883 | 0.82 | HDAC8 (0.65) | HDAC8HDAC6HDAC1 | |
| SCHEMBL355341 | 0.82 | CA1 (0.51) | CA1CA2ACHEHDAC8HDAC6 | |
| SCHEMBL10247274 | 0.82 | HDAC8 (0.54) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL354884 | 0.80 | HDAC8 (0.54) | HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CA1 506/4885CA2 450/4885ACHE 3488/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CA1 725/4885CA2 810/4885ACHE 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.